Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Synonyms

alpha-heparin

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Dalteparin sodium	12M44VTJ7B	Not Available	Not applicable

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Fragmin	Injection	15000 [iU]/0.6mL	Subcutaneous	Eisai Limited	1994-12-22	2016-09-30
Fragmin	Injection	2500 [iU]/0.2mL	Subcutaneous	Pfizer Laboratories Div Pfizer Inc	2015-04-01	Not applicable
Fragmin	Solution	25000 unit	Intravenous; Subcutaneous	Pfizer	1997-11-27	Not applicable
Fragmin	Solution	18000 unit	Intravenous; Subcutaneous	Pfizer	2011-02-01	Not applicable
Fragmin	Injection	5000 [iU]/0.2mL	Subcutaneous	Eisai Limited	1994-12-22	2016-09-30
Fragmin	Injection	12500 [iU]/0.5mL	Subcutaneous	Eisai Limited	1994-12-22	2016-09-30
Fragmin	Injection	18000 [iU]/0.72mL	Subcutaneous	Pfizer Laboratories Div Pfizer Inc	2015-04-01	Not applicable
Fragmin	Injection	7500 [iU]/0.3mL	Subcutaneous	Pfizer Laboratories Div Pfizer Inc	2015-04-01	Not applicable
Fragmin	Injection	10000 [iU]/1mL	Subcutaneous	Eisai Limited	1994-12-22	2016-09-30
Fragmin	Solution	15000 unit	Intravenous; Subcutaneous	Pfizer	2011-02-01	Not applicable

International/Other Brands

Boxol (Pharmacia) / Eurodal (Gland) / Ligoframin (Pfizer) / Low Liquemine (Roche)

Categories

UNII

S79O08V79F

CAS number

9005-49-6

Weight

Not Available

Chemical Formula

Not Available

InChI Key

Not Available

InChI

Not Available

IUPAC Name

Not Available

SMILES

Not Available

Pharmacology

Indication

Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications.

Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).

It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.

Associated Conditions

Pharmacodynamics

Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.

Mechanism of action

Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage.

Target	Actions	Organism
AAntithrombin-III	potentiator	Humans
AVascular endothelial growth factor A	inhibitor	Humans
ATissue factor pathway inhibitor	inhibitor	Humans
UP-selectin	inhibitor	Humans

Absorption

Almost completely absorbed after subcutaneous (sc) doses, with a bioavialability of about 87%.

Volume of distribution

3 litres

Protein binding

Less than unfractionated heparin, which is more than 90%.

Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.

Route of elimination

After 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).

Half life

Terminal Half life: Intravenous - 2 hours. Subcutaneous - 3-5hours

Clearance

Excreted via kidneys. The plasma clearance rate is 33 mL/min.

Toxicity

Overdosage: hemorrhagic complications. Adverse Drug Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. (uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
(1,2,6,7-3H)Testosterone	The therapeutic efficacy of Dalteparin can be increased when used in combination with (1,2,6,7-3H)Testosterone.
(R)-warfarin	The risk or severity of bleeding can be increased when Dalteparin is combined with (R)-warfarin.
(S)-Warfarin	The risk or severity of bleeding can be increased when Dalteparin is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid	The risk or severity of hyperkalemia can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Dalteparin.
1-Testosterone	The therapeutic efficacy of Dalteparin can be increased when used in combination with 1-Testosterone.
18-methyl-19-nortestosterone	The therapeutic efficacy of Dalteparin can be increased when used in combination with 18-methyl-19-nortestosterone.
3,5-diiodothyropropionic acid	3,5-diiodothyropropionic acid may increase the anticoagulant activities of Dalteparin.
4-hydroxycoumarin	The risk or severity of bleeding can be increased when Dalteparin is combined with 4-hydroxycoumarin.
4-Hydroxytestosterone	The therapeutic efficacy of Dalteparin can be increased when used in combination with 4-Hydroxytestosterone.
5beta-dihydrotestosterone	The therapeutic efficacy of Dalteparin can be increased when used in combination with 5beta-dihydrotestosterone.

Food Interactions

Herbs (anticoagulant/antiplatelet properties such as ginseng, ginkgo, ginger, garlic)

References

General References

King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr;100(4):535-40. [PubMed:6367579]
Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980 Oct 16;303(16):902-7. [PubMed:6997743]
Ockelford PA, Patterson J, Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046-9. [PubMed:2559484]
Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577-84. [PubMed:2158151]
Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A: Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol. 1989;37(4):415-8. [PubMed:2557219]
Holmer E, Soderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16 Suppl 2:1-7. [PubMed:3744129]
Malm K, Dahlback B, Arnljots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003 Apr 15;111(5):1659-66. [PubMed:12655212]
Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006 Jul;91(7):976-9. Epub 2006 Jun 1. [PubMed:16757417]
Schmid P, Brodmann D, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19. [PubMed:19175499]
Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N: Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286-94. Epub 2006 Oct 25. [PubMed:17166617]
Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. [PubMed:11011804]
Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]

External Links

KEGG Drug: D03353
PubChem Substance: 347910371
Wikipedia: Dalteparin_sodium

ATC Codes

B01AB04 — Dalteparin

AHFS Codes

20:12.04.16 — Heparins

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Recruiting	Treatment	Antiphospholipid Syndrome in Pregnancy / Pregnancy Loss	1
1	Completed	Treatment	Clear Cell Sarcoma of the Kidney / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer	1
1, 2	Completed	Prevention	Neoplasms, Lung / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)	1
2	Completed	Treatment	Brain and Central Nervous System Tumors	1
2	Completed	Treatment	Cancer of the Ovary	1
2	Completed	Treatment	Embolism and Thrombosis	1
2	Completed	Treatment	Malignant Neoplasm of Pancreas / Thromboembolism	1
2	Completed	Treatment	Shock, Septic	1
2	Completed	Treatment	Sickle Cell Disorders / Vaso-Occlusive Crises	1
2	Completed	Treatment	Venous Thromboembolism (VTE)	1
2	Not Yet Recruiting	Treatment	Cerebral Venous Thrombosis	1
2	Recruiting	Treatment	BMI >30 kg/m2 / Malignancies / Venous Thromboembolism (VTE)	1
2	Recruiting	Treatment	Cancer-associated Thrombosis / Duodenal Cancer / Esophageal Cancers / Hepatobiliary Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach	1
2	Terminated	Supportive Care	Deep Vein Thrombosis (DVT) / Malignancies / Pulmonary Embolism (PE) / Thrombotic events / Venous Thromboembolism (VTE)	1
2	Terminated	Treatment	Deep Vein Thrombosis (DVT) / Neoplasms	1
2	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2, 3	Completed	Prevention	Hemodialysis Treatment / Thromboembolism	1
2, 3	Completed	Screening	Impaired Renal Function	1
2, 3	Completed	Treatment	Diabetic Foot Ulcers (DFU)	1
3	Active Not Recruiting	Prevention	Strokes	1
3	Active Not Recruiting	Supportive Care	Cerebral Vein Thrombosis / Deep Vein Thrombosis (DVT) / Gonadal Thrombosis / Hepatic Thrombosis / Mesenteric Thrombosis / Metastatic Malignant Neoplasm / Neoplasms, Malignant / Portal Vein Thrombosis / Pulmonary Embolism (PE) / Renal Vein Thrombosis / Splenic thrombosis / Venous Thromboembolism (VTE)	1
3	Completed	Prevention	Critical Illness / Deep Venous Thrombosis	1
3	Completed	Prevention	Neoplasms, Brain / Venous Thromboembolism (VTE)	1
3	Completed	Prevention	Postpartum / Venous Thromboembolism (VTE)	1
3	Completed	Supportive Care	Cervical Cancers / Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Unspecified Adult Solid Tumor, Protocol Specific / Veno-Occlusive Disease	1
3	Completed	Treatment	Arterial Thromboembolic Events / Nonvalvular Atrial Fibrillation	1
3	Completed	Treatment	Cancer, Breast / Colorectal Cancers / Lung Cancers / Prostate Cancer / Veno-Occlusive Disease	1
3	Completed	Treatment	Chronic Renal Failure (CRF)	1
3	Completed	Treatment	Complications, Pregnancy / Hypercoagulability / Pregnancy	1
3	Completed	Treatment	Deep Vein Thrombosis (DVT) / Malignancies / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)	1
3	Completed	Treatment	Neoplasms / Venous Thromboembolism (VTE)	1
3	Completed	Treatment	Recurrent Abortion	1
3	Recruiting	Prevention	Traumatic Brain Injury (TBI)	1
3	Recruiting	Treatment	Venous Thromboembolism (VTE)	1
3	Terminated	Prevention	Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)	1
3	Terminated	Treatment	Malignant Neoplasm of Pancreas / Thromboembolism	1
3	Terminated	Treatment	Neoplasms / Venous Thromboembolism (VTE)	1
3	Unknown Status	Supportive Care	Lung Cancers / Thromboembolism	1
4	Completed	Prevention	Arthritis of the Hip / Infection NOS / Transfusion Related Complications / Wound Discharge	1
4	Completed	Prevention	Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)	1
4	Completed	Treatment	Deep Vein Thrombosis (DVT)	1
4	Completed	Treatment	Lower Extremity Superficial Thrombophlebitis / Superficial Thrombophlebitis / Upper Extremity Superficial Thrombophlebitis	1
4	Completed	Treatment	Lung Cancers	1
4	Completed	Treatment	Malignancies	1
4	Completed	Treatment	Malignant Neoplasm of Pancreas / Venous Thromboembolism (VTE)	1
4	Completed	Treatment	Superficial Thrombophlebitis	1
4	Recruiting	Prevention	Deep Venous Thrombosis / Pulmonary Embolism (PE)	1
4	Recruiting	Prevention	Renal Failure	1
4	Terminated	Not Available	Preeclampsia	1
4	Terminated	Prevention	Dalteparin / Deep Vein Thrombosis (DVT) / Thromboembolism	1
4	Terminated	Prevention	Venous Thromboembolism (VTE)	2
4	Terminated	Treatment	Myocardial Infarction / Unstable Angina Pectoris	1
Not Available	Active Not Recruiting	Prevention	Bone Cancer / Femur Fractures / Malignant Lymphomas / Neoplasms, Metastatic / Pathologic fracture / Plasma Cell Myeloma / Sarcoma, Bone / Soft Tissue Sarcoma (STS)	1
Not Available	Completed	Not Available	Acute Coronary Syndromes (ACS)	1
Not Available	Completed	Not Available	Acute Deep Vein Thrombosis	1
Not Available	Completed	Not Available	BMI >30 kg/m2	1
Not Available	Completed	Not Available	Thrombosis, Venous	1
Not Available	Completed	Not Available	Unsuspected Pulmonary Embolism	1
Not Available	Completed	Not Available	Venous Thromboembolism (VTE)	1
Not Available	Completed	Prevention	Thrombophylaxis in Transurethral Surgery	1
Not Available	Completed	Prevention	Venous Thromboembolism (VTE)	1
Not Available	Enrolling by Invitation	Treatment	Acute DVT of Lower Extremity	1
Not Available	Not Yet Recruiting	Treatment	Recurrent Pregnancy Losses / Undifferentiated Connective Tissue Disease	1
Not Available	Recruiting	Treatment	Blood Clots / Deep Vein Thrombosis (DVT) / Malignancies / Pulmonary Embolism (PE) / Venous Thromboembolism (VTE)	1
Not Available	Terminated	Diagnostic	Coagulation, Blood / Compression Devices, Intermittent Pneumatic / Postoperative Complications / Thrombelastography	1
Not Available	Terminated	Treatment	Antiphospholipid Antibody Syndrome / Recurrent Pregnancy Losses	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Injection	Subcutaneous	10000 [iU]/1mL
Injection	Subcutaneous	10000 [iU]/0.4mL
Injection	Subcutaneous	12500 [iU]/0.5mL
Injection	Subcutaneous	15000 [iU]/0.6mL
Injection	Subcutaneous	18000 [iU]/0.72mL
Injection	Subcutaneous	2500 [iU]/0.2mL
Injection	Subcutaneous	25000 [iU]/1mL
Injection	Subcutaneous	5000 [iU]/0.2mL
Injection	Subcutaneous	7500 [iU]/0.3mL
Solution	Intravenous; Subcutaneous	10000 unit
Solution	Intravenous; Subcutaneous	12500 unit
Solution	Intravenous; Subcutaneous	15000 unit
Solution	Intravenous; Subcutaneous	18000 unit
Solution	Intravenous; Subcutaneous	2500 unit
Solution	Intravenous; Subcutaneous	25000 unit
Solution	Intravenous; Subcutaneous	3500 unit
Solution	Intravenous; Subcutaneous	5000 unit
Solution	Intravenous; Subcutaneous	7500 unit
Liquid	Intravenous; Subcutaneous	2500 unit

Prices

Not Available

Patents

Not Available

Properties

State: Solid
Experimental Properties: Not Available
Predicted Properties: Not Available
Predicted ADMET features: Not Available

Spectra

Mass Spec (NIST): Not Available
Spectra: Not Available

Taxonomy

Classification: Not classified

Targets

Details1. Antithrombin-III

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Potentiator

General Function: Serine-type endopeptidase inhibitor activity
Specific Function: Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name: SERPINC1
Uniprot ID: P01008
Uniprot Name: Antithrombin-III
Molecular Weight: 52601.935 Da

References

Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165]
Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]

Details2. Vascular endothelial growth factor A

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Vascular endothelial growth factor receptor binding
Specific Function: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name: VEGFA
Uniprot ID: P15692
Uniprot Name: Vascular endothelial growth factor A
Molecular Weight: 27042.205 Da

References

Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010 Oct 12. [PubMed:21091776]
Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10. [PubMed:17692905]
Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]

Details3. Tissue factor pathway inhibitor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Serine-type endopeptidase inhibitor activity
Specific Function: Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action...
Gene Name: TFPI
Uniprot ID: P10646
Uniprot Name: Tissue factor pathway inhibitor
Molecular Weight: 35014.835 Da

References

Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev. 2004 Summer;22(2):121-34. [PubMed:15179449]
Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M: Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. Epub 2010 Aug 3. [PubMed:20682597]
Bendz B, Andersen TO, Sandset PM: Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. [PubMed:10847421]

Details4. P-selectin

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sialic acid binding
Specific Function: Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligan...
Gene Name: SELP
Uniprot ID: P16109
Uniprot Name: P-selectin
Molecular Weight: 90833.105 Da

References

Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537]

Enzymes

Details1. Heparanase

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Substrate

General Function: Syndecan binding
Specific Function: Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Se...
Gene Name: HPSE
Uniprot ID: Q9Y251
Uniprot Name: Heparanase
Molecular Weight: 61148.17 Da

References

Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398]

Drug created on September 14, 2010 10:21 / Updated on April 21, 2019 01:36